

EVALUATION OF FDA VIDEO TELECONFERENCE APRIL 28, 1999

To help us plan for future stakeholder activities, we want your comments on today's teleconference. Please fill out this form and leave it with the FDA coordinator at your downlink site.

Accessibility to stakeholders?

Broadcast length?

Good length and division of time

Broadcast format? (conversations with Drs. Henney and Suydam, use of studio audience, use of "talk show" style, phoned and faxed questions, etc.) _

Commissioner's statements & response to questions at the beginning was good. She is well spoken.

Subject matter covered?

Children weren't mentioned although an important part of FDAMA deals with studies in children.

Usefulness to stakeholders?

Audience should have a more extensive outline of FDAMA before the show.

EVALUATION OF FDA VIDEO TELECONFERENCE APRIL 28, 1999

To help us plan for future stakeholder activities, we want your comments on today's teleconference. Please fill out this form and leave it with the FDA coordinator at your downlink site.

Accessibility to stakeholders? *Excellent -*

Broadcast length? *about right*

Broadcast format? (conversations with Drs. Henney and Suydam, use of studio audience, use of "talk show" style, phoned and faxed questions, etc.) _

Excellent

Subject matter covered? *Would like to have had more
agency balance - i.e. more info on food safety
modernization efforts*

Usefulness to stakeholders? *Very*

EVALUATION OF FDA VIDEO TELECONFERENCE APRIL 28, 1999

To help us plan for future stakeholder activities, we want your comments on today's teleconference. Please fill out this form and leave it with the FDA coordinator at your downlink site.

Accessibility to stakeholders?

Very accessible

Broadcast length? Very good

Broadcast format? (conversations with Drs. Henney and Suydam, use of studio audience, use of "talk show" style, phoned and faxed questions, etc.) _

Very good

Subject matter covered?

good

Usefulness to stakeholders?

Good to see FDA decision makers

EVALUATION OF FDA VIDEO TELECONFERENCE

APRIL 28, 1999

To help us plan for future stakeholder activities, we want your comments on today's teleconference. Please fill out this form and leave it with the FDA coordinator at your downlink site.

Accessibility to stakeholders?

good

Broadcast length?

good

Broadcast format? (conversations with Drs. Henney and Suydam, use of studio audience, use of "talk show" style, phoned and faxed questions, etc.) _

good

Subject matter covered?

too general - not very helpful

Usefulness to stakeholders?

potentially very helpful, but this one really wasn't

EVALUATION OF FDA VIDEO TELECONFERENCE

APRIL 28, 1999

To help us plan for future stakeholder activities, we want your comments on today's teleconference. Please fill out this form and leave it with the FDA coordinator at your downlink site.

Accessibility to stakeholders?

Excellent

Broadcast length?

*a bit more for myto be given to
guests*

Broadcast format? (conversations with Drs. Henney and Suydam, use of studio audience, use of "talk show" style, phoned and faxed questions, etc.)

Excellent

Subject matter covered?

*Distribution of question sheet
via site is advised.*

Usefulness to stakeholders?

Very Informative

EVALUATION OF FDA VIDEO TELECONFERENCE
APRIL 28, 1999

To help us plan for future stakeholder activities, we want your comments on today's teleconference. Please fill out this form and leave it with the FDA coordinator at your downlink site.

Accessibility to stakeholders?

good

Broadcast length?

good - just right

Broadcast format? (conversations with Drs. Henney and Suydam, use of studio audience, use of "talk show" style, phoned and faxed questions, etc.)

very good,

Subject matter covered?

*Broad.
but I understand more
directed i.e. Biological discussion
are to be held*

Usefulness to stakeholders?

*This would be an excellent forum to
present new/proposal regulation*

EVALUATION OF FDA VIDEO TELECONFERENCE

APRIL 28, 1999

To help us plan for future stakeholder activities, we want your comments on today's teleconference. Please fill out this form and leave it with the FDA coordinator at your downlink site.

Accessibility to stakeholders?

VERY ACCESSIBLE & PUBLISHED

Broadcast length?

2 HRS GOOD ALTHOUGH I THOUGHT IT WAS TOO BROAD.

Broadcast format? (conversations with Drs. Henney and Suydam, use of studio audience, use of "talk show" style, phoned and faxed questions, etc.)

GOOD FORMAT

Subject matter covered?

MOST OF IT WAS INTERESTING ALTHOUGH I THINK THERE WERE TOO MANY SUBJECTS COVERED.

Usefulness to stakeholders?

DEPENDS ON AREA OF INTEREST, MAY WANT TO CONSIDER BREAKING OFF INTO SECTIONS FOR FOOD VS. DRUGS & DEVICE VS. SERVICES.

EVALUATION OF FDA VIDEO TELECONFERENCE APRIL 28, 1999

To help us plan for future stakeholder activities, we want your comments on today's teleconference. Please fill out this form and leave it with the FDA coordinator at your downlink site.

Accessibility to stakeholders?

Good accessibility → website

Broadcast length?

Good length of time — however, not enough time allowed for all questions — may consider lengthening by ~ 30 min.

Broadcast format? (conversations with Drs. Henney and Suydam, use of studio audience, use of "talk show" style, phoned and faxed questions, etc.)

Liked the broadcast format, style of "talk show", studio audience of "experts". Some questions rec'd by fax seem to be redundant — may consider screening questions

Subject matter covered?

Broad coverage of subject matter

Usefulness to stakeholders?

EVALUATION OF FDA VIDEO TELECONFERENCE

APRIL 28, 1999

To help us plan for future stakeholder activities, we want your comments on today's teleconference. Please fill out this form and leave it with the FDA coordinator at your downlink site.

Accessibility to stakeholders? *good*

Broadcast length? *fine*

Broadcast format? (conversations with Drs. Henney and Suydam, use of studio audience, use of "talk show" style, phoned and faxed questions, etc.) -

interesting, It would be nice to have an initial presentation of ideas from Dr. Henney and then begin the questions in the "talk show" style.

Subject matter covered? *very informative*

Usefulness to stakeholders?

very useful

EVALUATION OF FDA VIDEO TELECONFERENCE APRIL 28, 1999

To help us plan for future stakeholder activities, we want your comments on today's teleconference. Please fill out this form and leave it with the FDA coordinator at your downlink site.

Accessibility to stakeholders?

Good

Broadcast length?

Good

Broadcast format? (conversations with Drs. Henney and Suydam, use of studio audience, use of "talk show" style, phoned and faxed questions, etc.) -

Good - Easy to follow and interesting.

Subject matter covered?

Topics were almost too general to have max benefit to audience

Usefulness to stakeholders?

General information is good. It offered a nice forum for communicating FDA's policy and intent to implement.

EVALUATION OF FDA VIDEO TELECONFERENCE APRIL 28, 1999

To help us plan for future stakeholder activities, we want your comments on today's teleconference. Please fill out this form and leave it with the FDA coordinator at your downlink site.

Accessibility to stakeholders?

Good

Broadcast length?

There wasn't a whole lot of time for all the questions posed by such a wide group of stakeholders. More time would be ideal.

Broadcast format? (conversations with Drs. Henney and Suydam, use of studio audience, use of "talk show" style, phoned and faxed questions, etc.) _

Good

Subject matter covered?

Good

Usefulness to stakeholders?

Good